Production (Stage)
Antiaging Quantum Living Inc.
AAQL
$0.75
-$0.06-7.41%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10,806.67% | 5,989.66% | 5,862.50% | 1,580.65% | -44.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10,806.67% | 5,989.66% | 5,862.50% | 1,580.65% | -44.85% |
| Cost of Revenue | 48,587.50% | 2,375.00% | -- | -- | -- |
| Gross Profit | 6,295.52% | 6,355.70% | 5,621.88% | 1,572.58% | -50.74% |
| SG&A Expenses | 190.30% | 731.21% | 1,425.91% | 1,296.88% | 736.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 282.35% | 739.02% | 1,446.44% | 1,298.61% | 737.65% |
| Operating Income | -91.26% | -450.69% | -1,031.57% | -1,221.24% | -1,028.42% |
| Income Before Tax | -74.43% | -406.69% | -1,031.42% | -1,221.24% | -1,028.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.43% | -406.69% | -1,031.42% | -1,221.24% | -1,028.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.43% | -406.69% | -1,031.42% | -1,221.24% | -1,028.42% |
| EBIT | -91.26% | -450.69% | -1,031.57% | -1,221.24% | -1,028.42% |
| EBITDA | -59.06% | -379.13% | -920.50% | -1,169.27% | -1,018.46% |
| EPS Basic | -75.18% | -413.46% | -1,063.64% | -1,220.00% | -1,041.67% |
| Normalized Basic EPS | -74.42% | -409.09% | -1,050.00% | -1,288.89% | -1,128.57% |
| EPS Diluted | -75.18% | -413.46% | -1,063.64% | -1,220.00% | -1,041.67% |
| Normalized Diluted EPS | -74.42% | -409.09% | -1,050.00% | -1,288.89% | -1,128.57% |
| Average Basic Shares Outstanding | -0.03% | -0.03% | -0.03% | -0.03% | 0.00% |
| Average Diluted Shares Outstanding | -0.03% | -0.03% | -0.03% | -0.03% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |